KPIs & Operating Metrics(New)

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024)

Ginkgo Bioworks Holdings filings provide 2 years of Asset Writedowns and Impairment readings, the most recent being $47.9 million for Q2 2024.

On a quarterly basis, Asset Writedowns and Impairment rose 431.76% to $47.9 million in Q2 2024 year-over-year; TTM through Sep 2025 was $47.9 million, a 71.73% decrease, with the full-year FY2024 number at $4.8 million, down 96.03% from a year prior.
Asset Writedowns and Impairment hit $47.9 million in Q2 2024 for Ginkgo Bioworks Holdings, down from $121.4 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $121.4 million in Q4 2023 to a low of $16.2 in Q3 2023.